3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Conditions
Neoplasms
2
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Interventions
Cisplatin
76
Cetuximab
60
pembrolizumab
56
Radiotherapy, Intensity-Modulated
37
Radiotherapy
33
Carboplatin
31
Docetaxel
30
Fluorouracil
27
Nivolumab
26
Paclitaxel
20
Platinum
10
Albumin-Bound Paclitaxel
9
Surgical Procedures, Operative
8
Radiosurgery
8
Radiation
8
Erlotinib Hydrochloride
8
durvalumab
7
Bevacizumab
7
1,2-diaminocyclohexaneplatinum II citrate
7
epacadostat
6
Biopsy
6
Radiotherapy, Conformal
5
Ipilimumab
5
Immunoglobulin G
5
Gemcitabine
5
Capecitabine
5
130-nm albumin-bound paclitaxel
5
utomilumab
4
tremelimumab
4
palbociclib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Squamous Cell Carcinoma of Head and Neck
×
GSK-3326595
×
Clear all
NCT02783300
2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1
Completed
297 enrolled
76 charts